Characterizing complex biologics like antibody-drug conjugates (ADCs) requires solutions that go beyond traditional methods. In this Q&A, Mihir Thakar discusses how Phenomenex Biozen Native Reverse Phase columns, paired with high-resolution mass spectrometry, address the limitations of HIC, delivering new levels of precision, scalability, and efficiency in ADC analysis. Explore how these innovations are helping advance biopharma workflows: https://bit.ly/3W1KzJX
Danaher Life Sciences
Biotechnology Research
Framingham, Massachusetts 39,695 followers
Innovation at the speed of life
About us
The Life Sciences companies of Danaher integrate the deep scientific expertise of our individual operating companies with the robust engineering know-how of the Danaher Business System to create innovative workflows that significantly bend the drug development time curve. Every day, scientists around the world are working to understand the causes of disease, develop new therapies and vaccines, and test new drugs. These life science companies make this leading-edge scientific research possible. Our capabilities extend beyond research to power the creation of biopharmaceuticals, cell and gene therapies, and other breakthrough treatments to advance patient health and improve treatment outcomes. Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. We partner with customers across the globe to help them solve their most complex challenges, architecting solutions that bring the power of science to life. Our global teams are pioneering what’s next across Life Sciences, Diagnostics, Biotechnology and beyond.
- Website
-
https://lifesciences.danaher.com
External link for Danaher Life Sciences
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- Framingham, Massachusetts
- Type
- Public Company
Updates
-
Jingwen Ding, Ph.D. shares how the SCIEX Intabio ZT system with icIEF-UV/MS delivers reliable charge heterogeneity insights. Paired with EAD peptide mapping, these workflows enable multilevel characterization of ADC conjugation end products, advancing research and supporting high-quality drug development. Read the article: https://bit.ly/48n6MJR
-
Next week we’re heading to Festival of Biologics Europe 2025. Visit us at #Booth502 to meet experts from Genedata, Molecular Devices, Phenomenex and SCIEX. Learn how imaging, automation, analytics, AI and digital solutions can accelerate your biotherapeutic journey from discovery to commercialization. Review the full program and schedule time to connect: https://bit.ly/4nmtPc2
-
-
Protein solubility and native structure preservation are constant challenges in ADC analysis. Mihir Thakar from Phenomenex demonstrates how isopropanol (IPA) in Biozen methods offers milder elution than acetonitrile, helping maintain the integrity of complex biologics while delivering more reliable results. Watch the full webinar featuring solutions from SCIEX and Phenomenex to discover more practical strategies for biopharma analytical teams: https://bit.ly/4pzBE08
-
To bring better therapies to patients, drug discovery needs models that reflect human biology more accurately. 3D cell culture is transforming research by enabling more predictive insights and more reliable translation to the clinic. This blog explores how we are advancing 3D models to accelerate drug discovery and improve translational outcomes. Read the blog: https://bit.ly/4mHGxlV Learn more about our Analytical Solutions: https://bit.ly/4g8zGj4
-
With Cytiva’s new process development and formulation services for pDNA, mRNA, and LNPs, our portfolio expands to better serve customers shaping the future of medicine. This launch empowers scientists with solutions that are scalable and manufacturable, enabling breakthroughs from discovery through clinical development. Learn more: https://cytiva.link/asm02
Now announcing the launch of our new process development and formulation services for plasmid DNA (pDNA), mRNA and lipid nanoparticles (LNPs): This new offering represents a significant milestone in our mission to support customers from concept to clinic with scalable, reliable and manufacturable solutions. We look forward to helping steer you to success. Consider us a member of your team. Learn more: https://okt.to/8zdBDR
-
-
We are proud to be part of Danaher Corporation, a global community of 63,000+ associates innovating at the #speedoflife to improve human health. Discover Danaher’s impact: https://bit.ly/46L6DxN Learn more about Danaher Life Sciences: https://bit.ly/4lamFXV Abcam, Aldevron, Beckman Coulter Life Sciences, Genedata, IDBS, Integrated DNA Technologies, Leica Microsystems, Molecular Devices, Phenomenex, SCIEX
-
In a recent webinar, Wayne Stallaert, Ph.D. shared a case study on how Leica Microsystems Cell DIVE platform and Abcam's antibody portfolio enable scalable, automated cell cycle mapping to extract rich single-cell data across large tissue microarrays. This approach helps uncover the mechanistic and molecular differences driving cancer cell proliferation. Read the article: https://bit.ly/4nio6Vm
-
AAV-based therapeutics hold enormous promise, but the cost and complexity of development remain significant barriers. By rethinking workflows, adopting scalable solutions, and improving data continuity, labs can make development more efficient and cost-effective without compromising quality. This blog explores how smarter, more connected approaches are advancing the development of AAV therapies. Read the blog: https://bit.ly/4p3jq6G Learn more about our Analytical Solutions: https://bit.ly/4g8zGj4
-
We accelerate the journey from discovery to therapy with solutions that enhance data accuracy, streamline workflows, and enable advanced R&D. By transforming scientific insights into actionable outcomes, our portfolio drives innovation in healthcare and supports healthier lives. Discover how Abcam, Aldevron, Beckman Coulter Life Sciences, Genedata, IDBS, Integrated DNA Technologies, Leica Microsystems, Molecular Devices, Phenomenex, and SCIEX are shaping the future of therapeutics: https://bit.ly/3V1bTb2